EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 707 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices... November 28, 2025 Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML September 14, 2026 Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... May 22, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... ESMO Congress 2024 Barcelona, Spain, 13-17 September Study Offers Insights on Health Problems among AYA Cancer Survivors
